BACKGROUND: Although the recommended treatment of hepatitis C continues to evolve as newer and more effective medications are made available, hepatitis C drug regimens consisting of a 3-drug combination of a protease inhibitor, pegylated interferon, and ribavirin were recommended by the American Association for the Study of Liver Diseases for the HCV genotype I beginning in 2011. Although more effective than the earlier standard of care, these regimens have complex dosing schedules, prolonged duration, and deleterious side effects. It has been shown that patients tend to discontinue these regimens prematurely. Specialty pharmacies offer specialized care management programs to hepatitis C patients, consisting of such services as regularly scheduled patient counseling, assessing regimen appropriateness, monitoring treatment progress, scheduling refill reminders, and coordinating patient care with prescribers. The use of specialty pharmacies by hepatitis C patients may improve persistence on the 3-drug hepatitis C regimens.
• Three-drug treatment regimens consisting of pegylated interferon, ribavirin, and a protease inhibitor were recommended in 2011 by the American Association for the Study of Liver Diseases for HCV genotype I hepatitis C treatment. These 3-drug regimens demonstrated higher cure rates compared with the previous standard of care, a 2-drug combination of pegylated interferon and ribavirin.
• Patients on multidrug hepatitis C regimens are at high risk of prematurely discontinuing treatment. Patients on the 3-drug regimens may be at greater risk for discontinuation than those on 2-drug regimens due to more complex dosing schedules, variable duration of treatment, and additional adverse events resulting from the addition of a third drug.
• Specialty pharmacies have been successful at improving regimen adherence and reducing the number of dose reductions in patients on 2-drug hepatitis C regimens.
What is already known about this subject
• This study provides evidence from a real-life practice setting that the benefits of using a specialty pharmacy, already established in studies investigating patients on 2-drug regimens, also extend to patients on 3-drug regimens.
• Patients using specialty pharmacy were significantly more likely to be persistent to a 3-drug hepatitis C regimen containing a protease inhibitor compared with those using retail pharmacies.
• Use of specialty pharmacies may be an even more attractive option, as new hepatitis C agents, which cost approximately $84,000 for the 12-week treatment regimen, enter the market, and payers and plan sponsors are faced with balancing improving outcomes from their hepatitis C patients and the significant treatment costs.
and provide several services targeted at optimizing outcomes for hepatitis C patients. Trained pharmacists and nurses specializing in hepatitis C provide counseling on medication usage, as well as education on medication self-administration, managing potential side effects, and responding to adverse drug reactions. Scheduled outreach calls are made to monitor patients' medication adherence, provide laboratory followup reminders, and evaluate hepatitis C-related quality of life. Results from viral response tests are monitored closely throughout the course of treatment by a pharmacist with specialized training on the treatment of hepatitis C to ensure that treatment duration is appropriate based on response-guided treatment algorithms. The pharmacy can also coordinate with the prescribing physician to ensure that appropriate medications are selected for each patient based on patient genotype, comorbidities, and treatment history. Specialty pharmacies can also intervene to stop therapy when further treatment is considered futile according to evidence-based prescribing guidelines, protecting patients from unnecessary drug exposure with potentially harmful side effects and ensuring efficient use of medications for payors. 7, 9 Evidence from previous studies have demonstrated that specialty pharmacies have been successful at improving medication adherence to 2-drug hepatitis C regimens and reducing the number of dose reductions required in hepatitis C patients. 15, 16 As new hepatitis C agents (i.e., sofosbuvir and simeprevir), which cost approximately $84,000 for the 12-week treatment regimen, enter the market, payers and plan sponsors are faced with balancing the improving outcomes from their hepatitis C patients and the significant treatment costs. Thus, the use of specialty pharmacy may be an even more attractive option to maximize the likelihood that patients successfully complete therapy.
The objective of this analysis was to compare the likelihood of completing a 3-drug hepatitis C regimen containing telaprevir between patients using a specialty pharmacy offering a disease-specific care management program and those using a retail pharmacy. This analysis focused on the use of 3-drug regimens containing telaprevir, which accounted for over 80% of patients initiating 3-drug regimens at the time of this analysis. 8 Patients on 3-drug regimens using boceprevir were excluded, since only 103 patients were eligible for inclusion in the retail pharmacy group. Due to separate prescribing guidelines for telaprevir and boceprevir, patients using these drugs could not be combined for a pooled analysis. As expected, however, the most recent change in guidelines has shifted patient care from the 3-drug regimen containing telaprevir to the multidrug regimen containing simeprevir or sofosbuvir.
■■ Methods Data Source and Patient Selection
A claims-based, retrospective, observational study was conducted using prescription claims and eligibility data from a a significant advancement in the treatment of genotype I hepatitis C occurred with the introduction of 2 protease inhibitor (PI) medications: telaprevir and boceprevir. 4, 5 These PI medications were used in addition to traditional pegylated interferon and ribavirin to provide a 3-drug combination treatment regimen. [4] [5] [6] [7] [8] [9] Studies had shown that treatment with the 3-drug regimen resulted in shorter average duration of treatment and significantly higher rates of sustained viral response (SVR) in HCV genotype I patients compared with the earlier standard of care: a 2-drug combination pegylated interferon and ribavirin. 6, 7 Achievement of SVR is an important clinical outcome for hepatitis C and has been associated with a lower risk of developing long-term complications, such as cirrhosis and hepatocellular carcinoma, 10 which results in lower health care utilization and reduced medical costs. 11 The availability of newer and more effective medications has resulted in the American Association for the Study of Liver Diseases (AASLD) modifying its guidance to include the daily sofosbuvir. 12 Although efficacy had improved with the 3-drug regimens, research suggested that persistence remained a challenge with the 3-drug and 2-drug regimens. A review of 13 studies examining 2-drug hepatitis C regimens indicated that treatment regimen completion rates were suboptimal, with 5%-50% of patients failing to take 80% or more prescribed doses. 13 Therefore, the addition of a PI to the 2-drug regimen could have exacerbated the risk for nonpersistence with the addition of a third drug, as compared with the earlier 2-drug regimens. The variable duration of treatment with 3-drug regimens also contributes to regimen complexity, a known barrier to optimal adherence. 9 Treatment duration for the 3-drug regimens must be individualized for each patient and depends on several factors, including the patient's treatment history of hepatitis C, the extent to which hepatitis C infection responded to earlier treatment, and the viral response to the 3-drug regimen. 14 Another roadblock to persistence can come in the form of regimen intolerance. Between 10%-21% of patients on 3-drug regimens have been reported to discontinue treatment due to adverse events such as fatigue and depression. 9 In order to maximize the likelihood of successfully completing the 3-drug regimens, patients require close clinical monitoring and coordination between the prescriber, pharmacist, and patient throughout the course of therapy. 7, 9 Even with the newer HCV genotype I therapies, individualized monitoring and ongoing patient evaluation play a role in ensuring regimen tolerance, optimizing adherence, and minimizing waste.
Hepatitis C patients face many challenges in managing their treatment, including complex dosing regimens, coordination with physicians' offices for timely follow-up appointments, and coping with uncomfortable adverse effects. Patients also require training to use self-injectable pegylated interferons. While retail and other pharmacies continue to dispense these medications, specialty pharmacies offer specialized care management programs for patients using hepatitis C medications large national pharmacy benefit management (PBM) company database housing prescription claims for patients for whom the PBM serves as the network claims processor. The PBM also operates an independent specialty pharmacy that serves patients across the United States. Thus, patients in the study could obtain their hepatitis C medications from the PBMoperated specialty pharmacy, external specialty pharmacies, home-delivery pharmacies, or retail pharmacies. Patients who used more than 1 dispensing channel to fill their hepatitis C medications were excluded from the analysis, since these patients did not have the opportunity to take advantage of all the possible care management interventions offered by a single dispensing channel throughout the course of therapy. Claims for the period from July 1, 2011, to June 30, 2013, were used in this analysis. Patients were selected if they started a new 3-drug regimen consisting of pegylated interferon, ribavirin, and telaprevir between January 1, 2012, and June 30, 2012. At a minimum, patients were required to fill at least 1 claim for telaprevir, pegylated interferon, and ribavirin during the follow-up period to be included in the study. A new start on the regimen was defined by a gap of at least 180 days between the index claim of the 3-drug regimen and any previous claim for a hepatitis C medication. Hepatitis C medications were identified based on the National Drug Code number (for a list of drugs used, see the Appendix, available in the online article). Patients were followed for up to 365 days after the index hepatitis C claim. All study patients were continuously eligible for pharmacy benefits for at least 180 days before and 365 days after the index hepatitis C claim. Patients were assigned to study groups based on whether the patient used the PBM-operated specialty pharmacy or retail pharmacies to fill their hepatitis C prescriptions.
Study Outcome
Persistence to medication is typically measured at a fixed time after therapy initiation, usually after a predetermined fixed interval or at the end of the follow-up period. 17 However, the duration of therapy for 3-drug regimens containing telaprevir is not fixed. The optimum duration of treatment is determined on an individual basis throughout the course of therapy based on the response of the hepatitis C virus to treatment at predetermined intervals. The optimum duration of treatment with telaprevir may vary between 24 or 48 weeks. Guidelines recommend that HCV genotype I patients be initiated on concurrent triple-therapy with telaprevir, pegylated interferon, and ribavirin. 18 All patients who show evidence of responding to treatment (HCV ribonucleic acid [RNA] undetectable or < 1,000 international units per milliliter [IU/mL] at treatment weeks 4 and 12) should continue concurrent triple-therapy until treatment week 12 and then continue treatment with pegylated interferon and ribavirin from treatment week 12 to treatment week 24. Further treatment beyond week 24 may be required for some patients depending on a number of factors, such as cirrhotic status, response to current treatment regimen, and outcomes from previous treatment (e.g., null or partial responder). 9 Thus, completing the regimen through week 24 is a treatment milestone common to all patients using 3-drug regimens containing telaprevir. For this study, patients were defined as persistent at week 24 of therapy if they filled 84 days' supply (12 weeks) of telaprevir, 168 days' supply (24 weeks) of pegylated interferon, and 168 days' supply (24 weeks) of ribavirin.
Statistical Analysis
Unadjusted differences between the retail and specialty pharmacy groups were evaluated using t-tests for continuous variables and chi-squared tests for categorical variables (alpha set a priori to 0.05). A multivariate logistic regression model was created with regimen persistence as the dichotomous dependent variable (1 = persistent at week 24 of therapy, 0 = not persistent), pharmacy type as the primary predictor (specialty or retail), and other covariates. Days persistent to the 3-drug regimen were calculated as the number of days between therapy initiation and the first instance of discontinuation of any of the 3 drugs in the regimen. Differences in days persistent to therapy between specialty pharmacy and retail pharmacy were compared using Kaplan Meier survival analysis and a log-rank test to compare the 2 survival curves. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).
Factors known to confound the relationship between persistence and channel were identified based on a literature review. Covariates for these factors or their proxies were generated from the pharmacy claims data and controlled in the multivariate analysis. Demographic confounders included patient age in 2012, patient gender, and U.S. region where the patient resided in 2012, based on the U.S. Census regional classification of states. 19 Patient out-of-pocket payment was defined as the average of the patient-paid amount (sum of copayment and deductible) per 30 days' supply of hepatitis C medication filled during the follow-up period. 15 The count of unique 2-digit Generic Product Indicator (GPI) codes observed in the patient's pharmacy claims record during the follow-up period was used as a proxy for patient medication burden. 15 Days of supply per unadjusted hepatitis C prescription was computed by dividing the total number of days' supply of hepatitis C medication filled during follow-up by the number of unadjusted hepatitis C prescriptions filled and was also included in the model as a covariate. 20 Sensitivity analyses were conducted evaluating the impact of modifying the study definition of persistence (Table 3 ). In the main analysis, patients were required to have medication on hand for 100% of the days in the follow-up period in order to be defined as persistent. In the first sensitivity analysis, assuming 90% of days of supply filled to be adequate, patients were defined as persistent if they filled 152 days of pegylated interferon and ribavirin and 76 days of telaprevir. In the second sensitivity analysis, assuming 80% of the days of supply at week 24 to be adequate, patients were defined as persistent if they filled 135 days of pegylated interferon and ribavirin and 68 days of telaprevir. Both sensitivity analyses were also repeated without relaxing the days of supply assumption for telaprevir, since the total recommended duration of therapy is only 84 days, compared with 168 days for the other 2 medications. Finally, the 33 patients dropped because their geographical locations were coded as "unknown" were added back into the analytic sample and the multivariate modeling was performed.
■■ Results
The patient selection procedure is outlined in Figure 1 . A total of 13,130 patients had at least 1 hepatitis C prescription claim between January 1, 2012, and July 30, 2012. Of these, 9,013 patients were continuously eligible for pharmacy benefits 180 days before and 365 days after their index hepatitis C claims in 2012. A further 4,736 patients were excluded because they were non-naïve (i.e., they had 1 or more hepatitis C claims during the 180 days prior to their index hepatitis C claims in 2012. The 4,277 remaining patients consisted of 2,557 patients on 3-drug regimens with telaprevir, 1,025 patients on 2-drug regimens, and 695 patients on 3-drug regimens with boceprevir. An additional 1,049 patients were excluded for not exclusively using a specialty or a retail pharmacy. After excluding an additional 33 patients whose geographical locations based on the U.S. Census regions were coded as "unknown," the final analytic sample included 1,475 patients on 3-drug regimens with telaprevir. Of these, 1,182 patients were in the specialty pharmacy group, and the remaining 293 patients were in the retail pharmacy group.
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FIGURE 1
Selection Algorithm and Count of Patients Included in a Patient Cohort of Hepatitis C Patients Between July 1, 2011, and December 31, 2013, in PBM Claims Data
Hepatitis C patients between January 1, 2012, and July 30, 2012 13,130
4,117
Number of patients excluded
Continuously eligible for pharmacy benefits 180 day before and 365 days after index claim 9,013
No hepatitis C claims in the 6 months prior to the index hepatitis C claim in 2012 4,277
1,720
Patients on a 3-drug regimen with telaprevir (at least 1 claim for pegylated interferon, ribavirin, and telaprevir each) 2,557
1,049
Patients exclusively using PBM-managed specialty pharmacy or retail pharmacies to fill hepatitis C prescriptions 1,508 33 Patients whose geographical location based on U.S. Census region is not coded as "unknown" 1,475 
Impact of Specialty Pharmacy on Telaprevir-Containing 3-Drug Hepatitis C Regimen Persistence
The demographic and clinical characteristics of the selected patients are found in Table 1 . The average patient age was approximately 54 years for both groups. A little over one-third of patients in both groups were female. About 36% of patients using the PBM specialty pharmacy resided in the South compared with just over 20% of retail pharmacy patients. Nearly half of all retail pharmacy patients resided in the Northeast. Days' supply per unadjusted hepatitis C prescription was, on average, 1.3 days higher in the specialty pharmacy group compared with the retail pharmacy group. Out-of-pocket spending per 30-day adjusted hepatitis C prescription and medication burden was not significantly different between the study groups. The percentage of patients persistent to 3-drug hepatitis C regimens containing telaprevir at day 168 (week 24) of therapy was 16.1 percentage points higher among patients using the specialty pharmacy compared with those using retail pharmacies (56.0% vs. 39.9%, P < 0.001; Figure 2) .
Patients in the specialty group had a higher likelihood of achieving persistence to the 3-drug hepatitis C regimen containing telaprevir at day 168 (week 24) of therapy compared with the retail group (unadjusted odds ratio [OR] = 1.92, 95% confidence interval [CI] = 1.48-2.49). Patient demographics have been found to be significant confounders in assessing the relationship between dispensing channel and medication persistence. 21 Previous research on chronic conditions of diabetes, hypertension, or high blood cholesterol suggest that patients who are either female or living in the Northeast have better adherence. Our study had similar findings. However, previous research found older individuals more likely to be adherent, whereas our results suggest younger adults were more adherent. Results from the multivariate adjusted model are 
Persistency Measurements by Pharmacy Channel
patients prescribed the newer high-cost hepatitis C agents (sofosbuvir and simeprevir), specialty pharmacy may be an option to assist patients in successfully completing therapy.
There are a number of potential reasons why patients using a specialty pharmacy may be more successful at being persistent to hepatitis C therapy compared with those using a retail pharmacy. Patients using the specialty pharmacy in our study had their hepatitis C medications conveniently delivered to the location of their choice and received timely refill reminders tailored to the telaprevir-based regimen. Patients were also supported by specially trained pharmacists and nurses who provided extensive regimen-specific education, administration training, and coping tips throughout their treatment. In addition, patients received scheduled, telephonic follow-up outreaches to ensure rapid resolution of any concerns or questions.
The specialty pharmacy in this study also coordinated with prescribers to ensure that treatment was continued appropriately and that treatment interruptions were minimized. In addition to ensuring appropriate therapy continuation, the specialty pharmacists actively monitored viral response to treatment and engaged with prescribers to ensure timely discontinuation of regimens meeting futility end points. Although clinically appropriate, efforts to stop therapy when determined to be futile may have reduced the observed persistence rates in the specialty pharmacy group. Nonetheless, this study found higher rates of persistence in the specialty pharmacy group, compared with the retail pharmacy group. Specific retail pharmacies may have offered similar services provided by the specialty pharmacy to hepatitis C patients. presented in Table 2 . After multivariate adjustment, patients in the specialty pharmacy group were 89% more likely to be persistent with the 3-drug regimen containing telaprevir at day 168 (adjusted OR = 1.89, 95% CI = 1.44-2.48). As in the main analysis, patients in the specialty pharmacy group were found to be significantly more likely to be persistent to a 3-drug regimen containing telaprevir compared with patients using retail pharmacy in all scenarios evaluated in the sensitivity analyses.
■■ Discussion
The primary study objective was to determine whether there were differences in 3-drug hepatitis C regimen persistence between patients exclusively using either specialty or retail pharmacies to receive their medications. Our findings showed that after adjusting for a number of known confounders, patients who used a single specialty pharmacy exclusively had 89% greater likelihood of higher 3-drug telaprevir-containing regimen persistence than patients who exclusively used a retail pharmacy. Results were robust to sensitivity analyses in which patients were defined as persistent even when they filled 80% or 90% of the days' supply of hepatitis C medication to be taken by treatment week 24 (day 168). Measuring persistence at treatment day 168 allowed the inclusion of all patients on telaprevir.
Although the AASLD released new guidelines in early 2014, recommending a change from teleprevir to sofosbuvir or simeprevir, the newer regimen guidelines still comprised multidrug treatment (e.g., sofosbuvir, weight-based ribavirin, and weekly pegylated interferon for 12 weeks). Research suggests that treatment complexity is negatively associated with medication persistence. Additionally, research suggests that medication cost may influence patient adherence. Thus, for thus, the extent to which incentives exist to promote the use of one particular pharmacy channel over another may impact the generalizability of this study. Additionally, some patients may have been required to continue therapy until treatment day 336 (48 weeks), which is not considered here. We were unable to control for the effect of the distribution of patient race, which has been shown to be an important determinant of treatment response and tolerability. 11, 23, 24 Further research may be needed to examine the impact of age and adherence to medications treating longer-term acute conditions, such as hepatitis C. Finally, although the analysis did not examine the most recent HCV guidelines, the analysis did examine the relationship between a complicated 3-drug regimen in the treatment of hepatitis C. We believe our findings to be applicable to the current HCV treatment guidelines, which requires the use of multiple medications for the treatment of HCV genotype I.
■■ Conclusions
This study found that patients using a specialty pharmacy that offered a disease-specific hepatitis C care management program were 89% more likely to be persistent to 3-drug hepatitis C regimens containing telaprevir until an important clinical milestone, at treatment day 168 (week 24). Plan sponsors, payers, and patients may benefit from the hepatitis C specific care model used by the specialty pharmacy evaluated in this study for newer hepatitis C therapies, such as simeprevir and sofosbuvir.
Limitations
This study has several limitations, many of which are derived from the exclusive use of pharmacy claims data for this analysis. HCV genotype information was not available for study patients; neither were medical claims and laboratory test results. All study patients using the 3-drug regimen were assumed to be appropriate. Since medication burden was used as a proxy for comorbidity burden, conditions in which treatment does not involve medication use might be underrepresented. Examples include nonoral chemotherapy treatments and conditions identified through administrative claims for durable medical equipment, such as urinary incontinence and ostomy product. 22 We used a possession-based measure of regimen persistence, assuming that medication possessed by the patient would be used as prescribed. Similar assumptions have been made in other studies of medication persistence based on prescription claims data. 17 An additional limitation is the presence of several uncontrolled confounders related to pharmacy benefit design: auto-refill programs, channel incentive programs, and copayment tier structure. The specialty pharmacy did not have an auto-refill program in place; however, we could not identify patients engaged in retail auto-refill programs, so our estimates of retail persistence might be inflated, and our study conclusions conservative. Benefit design and channel incentive vary significantly across client populations; 
